Jingfang Pharmaceutical-B (02595): The stock price has recently risen. The clinical project GFH375 combined with cetuximab is to be included in the breakthrough therapy certification list

Zhitongcaijing · 1d ago

Zhitong Finance App News, Jingfang Pharmaceutical-B (02595) issued an announcement. The board of directors of the company noticed a recent increase in the price of the company's shares and would like to inform the company's shareholders and potential investors about the latest business developments of the Group. The company's clinical project, GFH375 combined with cetuximab, was included in the Breakthrough Therapy (BTD) list by the Drug Evaluation Center of the State Drug Administration on September 18, 2026 to treat KRAS G12D mutant metastatic colorectal cancer that has previously failed chemotherapy based on oxaliplatin, fluorouracil, and irinotecan. The clinical project was applied for on August 13, 2026, and the publication deadline is September 24, 2026.

The company originally planned to announce the clinical project after it was officially included in the BTD list in accordance with market practice. However, in accordance with the relevant provisions of the “Listing Rules”, the review progress of this proposed inclusion in the BTD list will be announced at this stage. There is still a potential risk that the clinical project will not be approved after the announcement. Shareholders and potential investors of the company should act carefully when trading or planning to trade the company's securities. In view of the instructions in this announcement, the company plans not to make a separate announcement after the clinical project is officially included in the BTD list.

Following inquiries from the Company which were reasonable in the circumstances, the Board confirmed that as of the date of this announcement, the Board was unaware of any reason for the increase in share prices, nor was it aware of any insider information required to be disclosed under Part XIVA of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.